Glaukos (NYSE:GKOS) Price Target Raised to $110.00 at JPMorgan Chase & Co.

Glaukos (NYSE:GKOS) had its price objective hoisted by JPMorgan Chase & Co. from $108.00 to $110.00 in a research report report published on Thursday morning, Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock.

Other equities analysts also recently issued research reports about the company. Needham & Company LLC increased their price objective on Glaukos from $108.00 to $113.00 and gave the stock a buy rating in a report on Thursday. Mizuho raised their target price on Glaukos from $85.00 to $100.00 and gave the company a neutral rating in a report on Thursday, April 11th. Citigroup boosted their price target on Glaukos from $107.00 to $120.00 and gave the stock a buy rating in a research report on Monday, March 25th. Wells Fargo & Company increased their price objective on Glaukos from $103.00 to $110.00 and gave the company an overweight rating in a report on Thursday. Finally, StockNews.com downgraded Glaukos from a hold rating to a sell rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $107.00.

Glaukos Stock Performance

NYSE GKOS traded up $1.48 on Thursday, hitting $106.51. 507,497 shares of the company were exchanged, compared to its average volume of 497,055. The company has a debt-to-equity ratio of 0.78, a current ratio of 5.38 and a quick ratio of 4.78. Glaukos has a twelve month low of $49.19 and a twelve month high of $108.22. The company’s 50 day moving average price is $93.33 and its 200-day moving average price is $82.87.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.12). Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The firm had revenue of $85.60 million for the quarter, compared to analyst estimates of $79.60 million. During the same period last year, the firm earned ($0.59) earnings per share. Glaukos’s revenue for the quarter was up 15.8% compared to the same quarter last year. Analysts anticipate that Glaukos will post -2.16 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Alex R. Thurman sold 434 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $95.33, for a total transaction of $41,373.22. Following the sale, the chief financial officer now directly owns 54,166 shares in the company, valued at $5,163,644.78. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO Alex R. Thurman sold 434 shares of the stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $95.33, for a total value of $41,373.22. Following the completion of the transaction, the chief financial officer now owns 54,166 shares of the company’s stock, valued at $5,163,644.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 59,801 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $100.47, for a total value of $6,008,206.47. Following the completion of the sale, the chief operating officer now directly owns 101,845 shares in the company, valued at approximately $10,232,367.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 232,881 shares of company stock worth $21,965,491. 6.40% of the stock is currently owned by company insiders.

Institutional Trading of Glaukos

Several large investors have recently added to or reduced their stakes in GKOS. National Bank of Canada FI acquired a new stake in Glaukos in the 4th quarter valued at about $46,000. GAMMA Investing LLC bought a new position in Glaukos in the 4th quarter worth approximately $55,000. Quadrant Capital Group LLC lifted its holdings in Glaukos by 54.8% during the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock worth $74,000 after buying an additional 329 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Glaukos by 17.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock valued at $137,000 after buying an additional 270 shares during the last quarter. Finally, Caldwell Sutter Capital Inc. increased its stake in shares of Glaukos by 5,860.0% in the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock valued at $140,000 after buying an additional 1,465 shares during the period. 99.04% of the stock is owned by institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.